Skip to main content
SpringerLink
Log in

Why does atorvastatin inhibit renal crystal retention?

  • Original Paper
  • Published:
Urological Research Aims and scope Submit manuscript

Abstract

Recently, we reported that atorvastatin prevents renal tubular cell injury by oxalate and inhibits renal crystal retention. In this study, we investigated the mechanism by which atorvastatin inhibits renal crystal retention. Male Sprague-Dawley rats were separated into four experimental groups, and the ethylene glycol model of hyperoxaluria and the atorvastatin treatment model were analyzed. To clarify the mechanism by which atorvastatin inhibits renal crystal retention, the removed kidneys were used for the quantitative analysis of superoxide dismutase (SOD) and catalase. The subunits of the NADPH oxidase system were evaluated using real-time polymerase chain reaction analysis. Furthermore, the level of transforming growth factor-β (TGF-β) in kidney tissue was compared in each group. Atorvastatin treatment increased the SOD and catalase level compared with the stone-forming control group. Atorvastatin treatment decreased the expression of NOX-1 mRNA. Furthermore, the level of TGF-β was suppressed by atorvastatin treatment. We found that atorvastatin have inhibited calcium oxalate (CaOX) urolithiasis formation. We hypothesize that the mechanism of action of atorvastatin involves inhibiting TGF-β and NADPH oxidase, and increasing the SOD and catalase level. We believe that atorvastatin will be helpful in the treatment of CaOX urolithiasis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Siener R, Glatz S, Nicolay C et al (2003) Prospective study on the efficacy of a selective treatment and risk factors for relapse in recurrent calcium stone patients. Eur Urol 44:467–474

    Article  PubMed  Google Scholar 

  2. Khan SR (2005) Hyperoxaluria-induced oxaidative stress and antioxidants for renal protection. Urol Res 33:349–357

    Article  PubMed  CAS  Google Scholar 

  3. Takemoto M, Liao JK (2001) Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 21:1712–1719

    Article  PubMed  CAS  Google Scholar 

  4. Glorioso N, Troffa C, Filigheddu F et al (1999) Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 34:1281–1286

    PubMed  CAS  Google Scholar 

  5. Wassmann S, Laufts U, Muller K et al (2002) Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 22:300–305

    Article  PubMed  CAS  Google Scholar 

  6. Kim SI, Han DC, Lee HB (2000) Lovastatin inhibits transforming growth factor-beta1 expression in diabetic rat glomeruli and cultured rat mesangial cells. J Am Soc Nephrol 11:80–87

    PubMed  CAS  Google Scholar 

  7. Toblli JE, Ferder L, Stella I et al (2002) Effects of angiotensin II subtype 1 receptor blockade by losartan on tubulointerstitial lesions caused by hyperoxaluria. J Urol 168:1550–1555

    Article  PubMed  CAS  Google Scholar 

  8. Tsujihata M, Momohara C, Yoshioka I et al (2008) Atorvastatin inhibits renal crystal retention in a rat stone forming model. J Urol 180:2212–2217

    Article  PubMed  CAS  Google Scholar 

  9. Nebat C, Moutet M, Huet P et al (1993) Spectrophotometric assay of superoxide dismutase activity based on the activated autoxidation of a tetracyclic catechol. Anal Biochem 214:442–451

    Article  Google Scholar 

  10. Shevalye H, Stavniichuk R, Xu W et al (2010) Poly (ADP-ribose) polymerase (PARP) inhibition counteracts multiple manifestations of kidney disease in long-term streptozotocin-diabetic rat model. Biochem Pharmacol 79:1007–1014

    Article  PubMed  CAS  Google Scholar 

  11. Wheeler CR, Salzman JA, Elsayed NM (1990) Automated assays for superoxide dismutase, catalase, glutathione peroxidase and glutathione reductase activity. Anal Biochem 184:193–199

    Article  PubMed  CAS  Google Scholar 

  12. Babior BM (1999) NADPH oxidase: an update. Blood 93:1464–1476

    PubMed  CAS  Google Scholar 

  13. Griendling KK, Sorescu D, Ushio-Fukai M (2000) NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 86:494–501

    PubMed  CAS  Google Scholar 

  14. Suh YA, Arnold RS, Lassegue B et al (1999) Cell transformation by the superoxidegenerating oxidase mox1. Nature 401:79–82

    Article  PubMed  CAS  Google Scholar 

  15. Chabrashvili T, Kitiyakara C, Blau J et al (2003) Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. Am J Physiol Renal Integr Comp Physiol 285:R117

    CAS  Google Scholar 

  16. Mizuguchi Y, Miyajima A, Kosaka T et al (2004) Atorvastatin ameliorates renal tissue damage in unilateral ureteral obstruction. J Urol 172:2456–2459

    Article  PubMed  CAS  Google Scholar 

  17. Yoshioka I, Tsujihata M, Akane W et al (2011) Angiotensin type-1 receptor blocker candesartan inhibits calcium oxalate crystal deposition in ethylene glycol-treated rat kidneys. Urology. doi:10.1016/j.urology.2010.11.019

  18. Andreoli TE (2000) Free radicals and oxidative stress. Am J Med 108:650–651

    Article  PubMed  CAS  Google Scholar 

  19. Ebisuno S, Kohjimoto Y, Tamura M et al (1995) Adhesion of calcium oxalate crystal to Madin-Darby canine kidney cells and some effects of glycosaminoglycans on cell injuries. Eur Urol 28:68–73

    PubMed  CAS  Google Scholar 

  20. Toblli JE, Ferder L, Stella I et al (2001) Protective role of enalapril for chronic tubulointerstitial lesions of hyperoxaluria. J Urol 166:275–280

    Article  PubMed  CAS  Google Scholar 

  21. Antus B, Exton MS, Rosivall L (2001) AngiotensinII: a regulator of inflammation during renal disease? Int J Immunopathol Pharmacol 14:25–30

    PubMed  CAS  Google Scholar 

  22. Umekawa T, Hatanaka Y, Kurita T et al (2004) Effect of angiotensin II receptor blockage on osteopontin expression and calcium oxalate crystal deposition in the rat kidneys. J Am Soc Nephrol 15:635–644

    Article  PubMed  CAS  Google Scholar 

  23. Umekawa T, Tsuji H, Uemura H et al (2009) Superoxide from NADPH oxidase as second messenger for the expression of osteopontin and monocyte chemoattractant protein-1 in renal epithelial cells exposed to calcium oxalate crystals. Br J Urol 104:115–120

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, 565-0871, Japan

    Masao Tsujihata, Iwao Yoshioka, Akira Tsujimura, Norio Nonomura & Akihiko Okuyama

Authors
  1. Masao Tsujihata
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Iwao Yoshioka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Akira Tsujimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Norio Nonomura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Akihiko Okuyama
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masao Tsujihata.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tsujihata, M., Yoshioka, I., Tsujimura, A. et al. Why does atorvastatin inhibit renal crystal retention?. Urol Res 39, 379–383 (2011). https://doi.org/10.1007/s00240-011-0370-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00240-011-0370-1

Keywords

Search

Navigation